zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2012-9-4-16zdor-1316Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEСРАВНИТЕЛЬНАЯ ХАРАКТЕРИСТИКА КЛИНИКО-ЛАБОРАТОРНЫХ ОСОБЕННОСТЕЙ ВТОРИЧНОГО И DE NOVO ОСТРОГО МИЕЛОИДНОГО ЛЕЙКОЗА У ДЕТЕЙComparative Characteristics of CLINICAL and LABORATORY FEATURES of SECONDARY and DE NOVO acute myeloid leukemia in childrenРомашевскаяИ. П.RomashevskayaI. P.noemail@neicon.ruСавваН. Н.SavvaN. N.noemail@neicon.ruЛитвинкоН. П.LitvinkoN. P.noemail@neicon.ruАлейниковаО. В.AleinikovaO. V.noemail@neicon.ruРеспубликанский научно-практический центр радиационной медицины и экологии человека, г. ГомельRepublican Research Center for Radiation Medicine and Human Ecology, GomelРеспубликанский научно-практический центр детской онкологии, гематологии и иммунологии, г. МинскRepublican Research Center for Pediatric Oncology, Hematology and Immunology, Minsk201228122012048388Copyright © Ромашевская И.П., Савва Н.Н., Литвинко Н.П., Алейникова О.В., 20122012Ромашевская И.П., Савва Н.Н., Литвинко Н.П., Алейникова О.В.Romashevskaya I.P., Savva N.N., Litvinko N.P., Aleinikova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1316

Вторичные лейкозы у детей в большинстве случаев представлены острым миелоидным лейкозом (ОМЛ), индуцированным химио- и (или) лучевой терапией, другими химическими мутагенами после терапии злокачественного новообразования (ЗН) или приобретенной апластической анемии (ПАА). Целью данного исследования стало изучение клинико-лабораторных особенностей вторичного ОМЛ. В исследование были включены 9 пациентов со вторичным ОМЛ и 128 пациентов с de novo ОМЛ. Вторичный ОМ чаще регистрировался у девочек. Наибольший процент заболевших наблюдался в возрастной категории от 3 до 10 лет (медиана возраста 11,5 года), наиболее часто регистрируемой морфологией была М1-М2, однако статистически значимых различий с de novo ОМЛ не выявлено (p > 0,05). При сравнении клинических проявлений достоверных различий не выявлено (p > 0,5). При этом патология хромосомы 7 встречалась при вторичном ОМЛ достоверно чаще (р ≤ 0,01).

Secondary leukemias in children in most cases are acute myeloid leukemia (AML) cases induced by chemotherapy and/or radiotherapy and by other chemical mutagens after treatment of malignant neoplasms (MN) or acquired aplastic anemia (AAA). The purpose of this study was to evaluate the clinical and laboratory features of secondary AML. The study included 9 patients with secondary AML and 128 patients with de novo AML. The girls revealed secondary AML more often. The largest percentage of secondary AML cases was observed in the age group from 3 to 10 (age median: 11.5), the most frequently registered morphology was M1-M2, but statistically significant differences with de novo AML were not found (p > 0,05). When comparing the clinical manifestations, no significant differences were detected (p > 0,5). Meanwhile, the pathology of chromosome 7 with secondary AML was significantly the most prevalent (p ≤ 0,01).

детивторичный острый миелоидный лейкозchildrensecondary acute myeloid leukemiaReferencesThe incidence of secondary leukemias / G. Leone [et al.] // Haematologica. - 1999. - Vol. 84. - P. 937-945.The incidence of secondary leukemias / G. Leone [et al.] // Haematologica. - 1999. - Vol. 84. - P. 937-945.Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation / D. Barnard [et al.] // Blood. - 2002. - Vol. 100. - P. 427-434.Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation / D. Barnard [et al.] // Blood. - 2002. - Vol. 100. - P. 427-434.Bhatia, C. Second cancers in survivors of childhood cancer / C. Bhatia, C. Sklar // Nat. Rev. Cancer. - 2002. - № 2. - Р. 124-132.Bhatia, C. Second cancers in survivors of childhood cancer / C. Bhatia, C. Sklar // Nat. Rev. Cancer. - 2002. - № 2. - Р. 124-132.Therapy-related leukemia and myelodysplasia: susceptibility and incidence / G. Leone [et al.] // Haematologica. - 2007. - Vol. 92(10). - P. 1389-1398.Therapy-related leukemia and myelodysplasia: susceptibility and incidence / G. Leone [et al.] // Haematologica. - 2007. - Vol. 92(10). - P. 1389-1398.Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia / C. H. Pui [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 7936-7941.Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia / C. H. Pui [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 7936-7941.Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1974-2001 and on 5098 unselected cases reported in the literature 1974-2001 / N. Mauritzson [et al.] // Leukemia. - 2002. - Vol. 16. - P. 2366-2378.Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1974-2001 and on 5098 unselected cases reported in the literature 1974-2001 / N. Mauritzson [et al.] // Leukemia. - 2002. - Vol. 16. - P. 2366-2378.Pedersen-Bjergaard, J. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation / J. Pedersen-Bjergaard, J. D. Rowley // Blood. - 1994. - Vol. 83. - P. 2780-2786.Pedersen-Bjergaard, J. The balanced and unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation / J. Pedersen-Bjergaard, J. D. Rowley // Blood. - 1994. - Vol. 83. - P. 2780-2786.Pedersen-Bjergaard, J. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II / J. Pedersen-Bjergaard, P. Phillip // Blood. - 1991. - Vol. 78. - P. 1147-1148.Pedersen-Bjergaard, J. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II / J. Pedersen-Bjergaard, P. Phillip // Blood. - 1991. - Vol. 78. - P. 1147-1148.Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting at DNA-topoisomerase II / H. J. Gill Super [et al.] // Blood. - 1993. - Vol. 82. - P. 3705-3711.Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting at DNA-topoisomerase II / H. J. Gill Super [et al.] // Blood. - 1993. - Vol. 82. - P. 3705-3711.Pedersen-Bjergaard, J. Two different classes of therapy-related and de novo acute myeloid leukemia? / J. Pedersen-Bjergaard, P. Philip // Cancer Genet Cytogenet. - 1991. - Vol. 55. - P. 119-124.Pedersen-Bjergaard, J. Two different classes of therapy-related and de novo acute myeloid leukemia? / J. Pedersen-Bjergaard, P. Philip // Cancer Genet Cytogenet. - 1991. - Vol. 55. - P. 119-124.Risk factors for evolutions of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children / S. Kojima [et al.] // Blood. - 2002. - Vol. 100. - P. 786-790.Risk factors for evolutions of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children / S. Kojima [et al.] // Blood. - 2002. - Vol. 100. - P. 786-790.Genetics of therapy-related myelodysplasia and acute myeloid leukemia / J. Pedersen-Bjergaard [et al.] // Leukemia. - 2008. - Vol. 22. - P. 240-248.Genetics of therapy-related myelodysplasia and acute myeloid leukemia / J. Pedersen-Bjergaard [et al.] // Leukemia. - 2008. - Vol. 22. - P. 240-248.

The authors declare that there are no conflicts of interest present.